Teacher Retirement System of Texas Invests $177,000 in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Teacher Retirement System of Texas purchased a new stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 16,669 shares of the company’s stock, valued at approximately $177,000.

Other large investors also recently modified their holdings of the company. Intech Investment Management LLC acquired a new stake in shares of Neumora Therapeutics in the 3rd quarter valued at about $175,000. Charles Schwab Investment Management Inc. increased its stake in Neumora Therapeutics by 139.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company’s stock worth $9,224,000 after acquiring an additional 406,891 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of Neumora Therapeutics during the 3rd quarter worth approximately $1,097,000. State Street Corp lifted its position in shares of Neumora Therapeutics by 65.3% during the 3rd quarter. State Street Corp now owns 1,790,707 shares of the company’s stock worth $23,655,000 after buying an additional 707,409 shares during the last quarter. Finally, Wexford Capital LP grew its position in Neumora Therapeutics by 90.1% in the third quarter. Wexford Capital LP now owns 217,879 shares of the company’s stock valued at $2,878,000 after acquiring an additional 103,285 shares during the last quarter. 47.65% of the stock is currently owned by institutional investors.

Neumora Therapeutics Stock Performance

Neumora Therapeutics stock opened at $0.94 on Thursday. The stock has a market cap of $152.33 million, a PE ratio of -0.50 and a beta of 2.59. Neumora Therapeutics, Inc. has a fifty-two week low of $0.89 and a fifty-two week high of $17.19. The firm’s 50-day simple moving average is $1.55 and its 200 day simple moving average is $7.33.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09. As a group, analysts predict that Neumora Therapeutics, Inc. will post -1.61 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

NMRA has been the subject of several research reports. Bank of America reiterated an “underperform” rating and issued a $1.00 target price (down from $7.00) on shares of Neumora Therapeutics in a research report on Wednesday. Stifel Nicolaus lowered shares of Neumora Therapeutics from a “buy” rating to a “hold” rating and dropped their target price for the company from $6.00 to $2.00 in a report on Friday, March 7th. Guggenheim downgraded shares of Neumora Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, March 7th. William Blair lowered Neumora Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, March 10th. Finally, HC Wainwright decreased their price target on shares of Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Neumora Therapeutics has a consensus rating of “Hold” and a consensus target price of $9.29.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.